Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.
about
Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and DevelopmentAsymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic reviewThe issue of plasma asymmetric dimethylarginine reference range - A systematic review and meta-analysisThe Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular DiseaseHypothermia decreases cerebrospinal fluid asymmetric dimethylarginine levels in children with traumatic brain injury.Pilot study of the association of the DDAH2 -449G polymorphism with asymmetric dimethylarginine and hemodynamic shock in pediatric sepsis.Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.Left atrial volume index and aortic stiffness index in adult hemodialysed patients--link between compliance and pressure mediated by endothelium dysfunction; a cross-sectional studyNitric oxide synthetic pathway in red blood cells is impaired in coronary artery disease.Endothelial dysfunction and cardiovascular disease.Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disordersPlasma asymmetric dimethylarginine predicts restenosis after coronary angioplastyL-citrulline for protection of endothelial function from ADMA-induced injury in porcine coronary artery.Left ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertensionEvaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.Asymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1Therapeutic use of citrulline in cardiovascular disease.Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort.Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular riskEndothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clamp.The impact of fiber supplementation on ADMA levelsADMA and SDMA levels in healthy men exposed to tobacco smoke.Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide productionEndogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?Association between serum levels of carotenoids and serum asymmetric dimethylarginine levels in Japanese subjectsLevels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants.A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease.Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency.Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
P2860
Q28070134-B81E22C3-1FC7-4B35-B1FC-05FCCEDD35D7Q28075206-74C4FBA4-3B4A-4CDC-AC66-8CA57CD2174AQ30300218-896337CD-A713-4BA8-9650-3A026AE9A34BQ33582151-5632917F-EA94-4A77-A3C0-4E3CB11D5F67Q33646665-67DE438D-7D9C-4E77-B281-A61C18761EEAQ33664224-439B2A9D-A98A-4AA9-914A-E0BF23C7FFCFQ33940891-A6F04C80-BB6C-47E7-BC7C-D10CFB5185EAQ34053465-370D87FB-67CA-4360-9552-902F94AD7ABFQ34200808-04797386-43B7-48B3-8CCF-7163DD357F24Q34201581-1146561A-81C9-4C66-A6EA-FC7CD188E678Q34466020-449C4FB6-C51D-4787-B6A9-BB6C74DE29D0Q34934327-D82BA130-8228-4FE5-A991-F2C0C5FA19D6Q35156621-8FE63A5A-5A7B-4007-BCA2-142C22088BBBQ35590733-C56E0CDC-1DB5-41BC-8174-DCF359FAEA79Q35674171-BCE991A2-AB40-4520-9EBD-65411F409984Q35687456-EB2C3C5F-46C2-451A-A8B1-D25AFCB6EB47Q35829220-931F22E6-5066-416B-9716-059BB2F1FC46Q36083890-888B6E78-9D60-41FB-8B52-9BADAD8C1873Q36647252-FEC93705-A9B5-4ADF-859D-D7D24FC2C0F4Q36703841-1D9FFCB9-C83C-4C14-9D35-AF150B1351F4Q36846899-F1AA3AB3-F89B-46CB-A83C-71FF94ACDB4AQ37211043-CA0BAB40-AF17-4EDF-9A03-391E4011DCC6Q37222244-7C591BA3-52FE-42EB-96E2-8C716FEB2D11Q37224328-35381F14-93F0-4D10-9AEF-18B370048A76Q37359838-1D47BD73-4C90-432A-B249-8C577A3BFD00Q37365823-A412FC54-94DB-4165-9440-7E42D85B6393Q37370528-86DC3F6A-1A80-4169-8D0C-257D5291366CQ37370572-3E323C04-A2CB-42B2-A0DD-F41EAFB908BAQ37403981-B833C7AE-D16D-4DD8-8936-0D32D5B12907Q37419545-FF19EF80-2A37-4A9C-8F1E-BA765506D367Q37462898-CB1E8269-AF6A-44A5-BE6D-A962557D0EACQ37467533-D4E5DB40-90C3-4986-A175-6AA54DACFFD2Q37580114-5776D4A3-271E-45A5-A4BB-279ED472C52CQ37684919-40813202-5679-411F-85C2-6A1847F8B400Q37725171-5334B655-1501-4CA2-81CB-A49D0D7F849BQ38468092-A1044545-7464-465F-92E1-084102D2F200Q38477549-A31C3C5C-650C-4558-A407-58F2C2C44960Q38540416-24E9F9F3-D4B0-4986-8C07-366B58C285A8Q38886946-756D960D-8A32-4878-B607-545191373B57Q39535124-1FA120F8-752E-47B9-A97D-949A60C958B6
P2860
Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@ast
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@en
Asymmetric dimethylarginine is ...... nfluence of ADMA Concentration
@nl
type
label
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@ast
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@en
Asymmetric dimethylarginine is ...... nfluence of ADMA Concentration
@nl
prefLabel
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@ast
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@en
Asymmetric dimethylarginine is ...... nfluence of ADMA Concentration
@nl
P2093
P1476
Asymmetric dimethylarginine is ...... Concentration (CARDIAC) study.
@en
P2093
Andreas Mügge
Asja Bartling
Bernd C Simon
Bernhard Maisch
Caroline Schmidt-Lucke
Christoph Hanefeld
Dietrich Strödter
Edzard Schwedhelm
Friedrich Schulze
Harald Tillmanns
P304
P356
10.1016/J.AHJ.2006.06.005
P407
P577
2006-09-01T00:00:00Z